Pioneering the next era of human longevity through precision medicine, AI-driven diagnostics, and breakthrough therapeutics. We don't just treat disease—we redefine biological potential.
Zenth Health Sciences operates across the full spectrum of biomedical innovation. From early-stage target discovery to global commercialization, our integrated platform leverages proprietary AI models, CRISPR-Cas12/13 systems, and decentralized clinical trial networks to accelerate life-saving interventions.
With 14 dedicated research institutes and strategic partnerships with 89 top-tier medical centers, we maintain a continuous pipeline of 47 novel compounds and 12 digital therapeutics in advanced development.
Our R&D engine is structured around four high-impact domains, each backed by dedicated capital and cross-functional expertise.
Next-generation CRISPR platforms delivering precise, in-vivo corrections for monogenic disorders, oncology targets, and inherited metabolic conditions.
Novel neuroprotective agents, biomarker-driven diagnostics, and closed-loop neuromodulation devices for Alzheimer's, Parkinson's, and treatment-resistant depression.
Multi-modal clinical AI that integrates radiology, pathology, and real-world data to enable early detection, risk stratification, and personalized treatment pathways.
Checkpoint inhibitors, CAR-T cell engineering, and tumor-agnostic targeted therapies designed to overcome resistance mechanisms and improve long-term survival.
AAV-mediated correction for Hereditary Transthyretin Amyloidosis
Bispecific T-cell engager for CD19+/CD22+ refractory B-cell malignancies
Wearable EEG + ML algorithm for early seizure prediction & closed-loop intervention
Whether you're a clinical site, biotech innovator, or institutional investor, explore how our integrated platform accelerates breakthrough therapeutics from bench to bedside.